查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1714826

研究抗体市场：按产品类型、技术、目标区域、来源类型、技术类型、结合物类型、生产方法、应用、最终用户 - 2025-2030 年全球预测

Research Antibodies Market by Product Type, Technology, Target Area, Source Type, Technology Type, Conjugate Type, Production Method, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年研究抗体市场价值将达到 67.9 亿美元，2025 年将成长至 73.6 亿美元，复合年增长率为 8.44%，到 2030 年将达到 110.5 亿美元。

主要市场统计数据
基准年2024年 67.9亿美元
预计2025年 73.6亿美元
预测年份 2030 110.5亿美元
复合年增长率（%） 8.44%

在生物技术不断进步和治疗需求不断发展的推动下，抗体市场正经历一段动态成长和进步时期。本报告详细探讨了这一形势，解决了市场复杂性和创新步伐加快的问题。它强调了研究抗体对于增强诊断能力、有效的治疗性介入和尖端研究工具的重要性。分子工程的最新趋势，加上对精准医疗日益增长的需求，正在为市场带来翻天覆地的变化。在过去几年中，该行业对新一代抗体开发、改进的生产方法以及与治疗领域一致的先进细分策略的投资不断增加。随着学术机构、研究组织和製药业相关人员寻求创新解决方案，对全面策略分析的需求比以往任何时候都更加强烈。该报告旨在揭示关键的成长动力、新兴趋势和关键见解，以显示市场的强大潜力和转型轨迹。

改变研究抗体市场

抗体领域的最新发展揭示了由技术突破和不断变化的市场需求所催化的变革性转变。随着公司改进生产技术并采用尖端方法，市场模式正在转变。次世代定序、优化的细胞培养系统和增强的精製方法等发展正在重新定义抗体开发的速度和效率。此外，In Silico方法与高通量筛检过程的结合可以最大限度地降低成本和时间障碍，加速从研究到商业应用的进程。这些创新进展不仅促进了更严格的临床试验，也拓宽了其应用范围。对品管和法规遵从性的日益关注也营造了更受最终用户信任和采用的环境。随着市场的扩大，相关人员现在可以从更高的诊断准确性和更有针对性的治疗性介入受益，这在精准医疗成为常态的环境中至关重要。预计技术成熟度和市场应对力之间的相互作用将开启各个细分市场更大创新和策略投资的时代。

抗体市场的关键细分洞察

对市场区隔的详细分析揭示了几个关键方面，可以明确消费者需求和市场动态。分析将涵盖产品类型、单株、多株抗体和重组抗体等多个面向。具体来说，单株抗体可分为生物类似抗体、嵌合体抗体、人源化抗体、鼠源性单株抗体等细小的次子区隔多株抗体可分为山羊来源和兔子来源。将透过体外和体内应用探索重组抗体，突显其独特的生产技术。然后，我们讨论构成现代抗体生产支柱的技术，重点在于生物素-亲和素、细胞表面暴露、重组抗体技术和超速离心等技术。基于目标区域的分析检视了心臟病学、感染疾病、神经病学、肿瘤学等重点领域，并进一步审查了神经病学部分，重点关注中枢神经系统和周围神经系统。此外，来源类型深入研究了鸡、山羊、小鼠和兔子等各种来源，而技术类型评估了从融合瘤技术到电脑抗体筛检、噬菌体展示和单域抗体技术等方法。此外，我们将重点放在生物素、酵素、萤光染料和金等结合物类型，区分体外和体内的生产方法，流式细胞技术、萤光和免疫组织化学等应用方法，以及福马林固定石蜡包埋和冷冻组织技术。最后，我们调查了最终用户，包括细分为基础研究和转化研究的学术研究组织、满足分析和临床前研究需求的受託研究机构，以及从事临床试验和研发的製药和生物技术公司。每个细分观点都为制定市场策略和将行业创新与以患者为中心的结果联繫起来提供了关键见解。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球慢性病和感染疾病的发生率不断上升
      • 个人化医疗和标靶治疗正受到全球关注
      • 增加对基于抗体的生命科学研究的投资
    • 限制因素
      • 创造新抗体的研发成本高昂
    • 机会
      • 整合生物技术进步，简化和优化抗体生产流程
      • 专注于多表位靶向抗体，以提高整体疾病疗效
    • 任务
      • 应对研究性抗体核准和分销方面的监管挑战
  • 市场区隔分析
    • 产品类型：单株抗体由于特异性提高和生物相似药替代品而越来越受到青睐
    • 最终用户：製药和生技公司扩大研究抗体的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 依产品类型研究抗体市场

  • 单株抗体
    • 生物相似抗体
    • 嵌合体和人源化抗体
    • 鼠源性单株抗体
  • 多株抗体
    • 山羊多株多株抗体
    • 兔多株抗体
  • 重组抗体
    • 体外重组抗体
    • 体内重组抗体

第七章 抗体市场研究（依技术）

  • 生物素-亲和素法
  • 细胞表面暴露
  • 重组抗体技术
  • 超速离心

第八章 依目标领域研究抗体市场

  • 心臟病学
  • 感染疾病
  • 神经病学
    • 中枢神经系统
    • 週边神经系统
  • 肿瘤学

第九章依来源类型研究抗体市场

  • 鸡
  • 山羊
  • 老鼠
  • 兔子

第十章以技术类型研究抗体市场

  • 融合瘤技术
  • In Silico抗体筛检
  • 噬菌体展示
  • 单域抗体技术

第11章依应用类型研究抗体市场

  • 生物素
  • 酵素
  • 萤光染料
  • 金子

第十二章 依製造方法研究抗体市场

  • 体外生产
  • 体内生产

第十三章抗体市场的应用研究

  • 流式细胞技术
  • 萤光
  • 免疫组织化学
    • 福马林固定石蜡包埋组织
    • 冷冻组织
  • 西方印渍术

第十四章 抗体市场研究（依最终用户）

  • 学术研究所
    • 基金会调查
    • 转化研究
  • 合约研究组织
    • 分析服务
    • 临床前研究
  • 製药和生物技术公司
    • 临床试验
    • 研究与开发

15.美洲研究抗体市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

16. 亚太研究抗体市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

17. 欧洲、中东和非洲研究抗体市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十八章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Absolute Antibody Ltd.
  • Agilent Technologies, Inc.
  • Atlas Antibodies
  • AvantGen, Inc.
  • Becton, Dickinson and Company
  • Bio X Cell
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio
  • GenScript Corporation
  • ImmunoPrecise Antibodies Ltd.
  • Jackson ImmunoResearch Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • PerkinElmer, Inc.
  • PROGEN Biotechnik GmbH
  • Proteintech Group, Inc.
  • QIAGEN NV
  • Revvity, Inc.
  • Rockland Immunochemicals, Inc.
  • Santa Cruz Biotechnology Inc.
  • Synaptic Systems GmbH
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4312A385A328

The Research Antibodies Market was valued at USD 6.79 billion in 2024 and is projected to grow to USD 7.36 billion in 2025, with a CAGR of 8.44%, reaching USD 11.05 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 6.79 billion
Estimated Year [2025] USD 7.36 billion
Forecast Year [2030] USD 11.05 billion
CAGR (%) 8.44%

The antibody market is witnessing a phase of dynamic growth and breakthroughs driven by continuous advancements in biotechnology and evolving therapeutic needs. This report provides an in-depth exploration of the landscape, addressing market complexities and the accelerating pace of innovation. The focus is on how research antibodies have become integral to enhanced diagnostic capabilities, effective therapeutic interventions, and cutting-edge research tools. Recent trends in molecular engineering combined with a rising demand for precision medicine set the stage for transformational market shifts. Over the past few years, the industry has seen increased investments into next-generation antibody development, improved production methodologies, and sophisticated segmentation strategies that cater to tailored therapeutic domains. With stakeholders across academia, research institutes, and the pharmaceutical industry seeking innovative solutions, the need for a comprehensive strategic analysis has never been greater. This report aims to articulate key growth drivers, emerging trends, and pivotal insights that underline the market's robust potential and transformative trajectory.

Transformative Shifts in the Antibody Landscape

Recent developments in the antibody sector reveal transformative shifts catalyzed by breakthroughs in technology and evolving market demands. Market paradigms are shifting as companies refine their production techniques and adopt cutting-edge methodologies. Advances such as next-generation sequencing, optimized cell-culture systems, and enhanced purification methods have redefined the speed and efficiency of antibody development. Furthermore, the integration of in silico approaches and high-throughput screening processes has minimized cost and time barriers, thereby accelerating the pipeline from research to commercial application. These transformative advancements have not only encouraged more robust clinical trials but also expanded the application spectrum. Increased focus on quality control and regulatory compliance has fostered a climate of increased trust and adoption among end users. As the market expands its reach, stakeholders now have the advantage of improved diagnostic accuracy and more targeted therapeutic interventions, which are essential in an environment where precision medicine is becoming the norm. The interplay between technological finesse and market readiness is anticipated to usher in an era of greater innovation and strategic investment across various market segments.

Key Segmentation Insights in the Antibody Market

An in-depth analysis of market segmentation reveals several pivotal dimensions that provide clarity on consumer needs and market dynamics. The analysis unfolds through multiple perspectives such as product type, where the market is dissected into monoclonal antibodies, polyclonal antibodies, and recombinant antibodies. Specifically, monoclonal antibodies command nuanced sub-segments including biosimilar antibodies, chimeric and humanized antibodies, and murine monoclonal antibodies; while polyclonal antibodies further branch into goat and rabbit sources. Recombinant antibodies are explored through their in vitro and in vivo applications, highlighting their unique production techniques. The examination then shifts to technology, emphasizing methods such as the biotin-avidin method, cell-surface exposure techniques, recombinant antibody technology, and ultracentrifugation, which collectively form the backbone of modern antibody production. An analysis based on target area explores critical fields including cardiology, infectious diseases, neurology, and oncology, with the neurology segment further scrutinized into central and peripheral nervous system focuses. In addition, source type segmentation delves into various origins including chicken, goat, mice, and rabbit, while technology type segmentation evaluates methods from hybridoma technology to in silico antibody screening, phage display, and single domain antibody technology. Additional considerations span conjugate types involving biotin, enzymes, fluorescent dyes, and gold; production methods that differentiate between in vitro and in vivo production; and application methods that detail flow cytometry, immunofluorescence, immunohistochemistry with further focus on formalin-fixed paraffin-embedded as well as frozen tissue techniques. Lastly, the analysis reviews the end user spectrum ranging from academic and research institutes with subdivisions in basic and translational research, contract research organizations servicing analytical and preclinical research needs, and pharmaceutical and biotechnology companies engaged in clinical trials and research and development. Each segmentation perspective provides essential insights that are instrumental in shaping market strategies and aligning industry innovation with patient-centric outcomes.

Based on Product Type, market is studied across Monoclonal Antibodies, Polyclonal Antibodies, and Recombinant Antibodies. The Monoclonal Antibodies is further studied across Biosimilar Antibodies, Chimeric and Humanized Antibodies, and Murine Monoclonal Antibodies. The Polyclonal Antibodies is further studied across Goat Polyclonal Antibodies and Rabbit Polyclonal Antibodies. The Recombinant Antibodies is further studied across In Vitro Recombinant Antibodies and In Vivo Recombinant Antibodies.

Based on Technology, market is studied across Biotin-Avidin Method, Cell-Surface Exposure, Recombinant Antibody Technology, and Ultracentrifugation.

Based on Target Area, market is studied across Cardiology, Infectious Diseases, Neurology, and Oncology. The Neurology is further studied across Central Nervous System and Peripheral Nervous System.

Based on Source Type, market is studied across Chicken, Goat, Mice, and Rabbit.

Based on Technology Type, market is studied across Hybridoma Technology, In Silico Antibody Screening, Phage Display, and Single Domain Antibody Technology.

Based on Conjugate Type, market is studied across Biotin, Enzymes, Fluorescent Dyes, and Gold.

Based on Production Method, market is studied across In Vitro Production and In Vivo Production.

Based on Application, market is studied across Flow Cytometry, Immunofluorescence, Immunohistochemistry, and Western Blotting. The Immunohistochemistry is further studied across Formalin-Fixed Paraffin-Embedded Tissues and Frozen Tissues.

Based on End User, market is studied across Academic And Research Institutes, Contract Research Organizations, and Pharmaceutical And Biotechnology Companies. The Academic And Research Institutes is further studied across Basic Research and Translational Research. The Contract Research Organizations is further studied across Analytical Services and Preclinical Research. The Pharmaceutical And Biotechnology Companies is further studied across Clinical Trials and Research And Development.

Key Regional Insights and Market Reach

Geographic analysis of the antibody market reveals distinct trends that vary significantly across global regions. The Americas continue to demonstrate robust market growth due to well-established research infrastructures and substantial clinical investments that have driven innovation in both diagnostic and therapeutic arenas. In contrast, Europe, the Middle East, and Africa offer a diverse landscape where regulatory reforms, emerging biotech hubs, and partnership opportunities have created fertile ground for expanding antibody research and production. Furthermore, the Asia-Pacific region is rapidly emerging as a significant contender due to increasing investments in biotechnology, supportive government policies, and a growing demand for affordable, high-quality therapeutic antibodies. These regional insights reflect a dynamic interplay between local market conditions and global technological advancements. With regulatory frameworks evolving to support innovation and clinical research, each region presents both challenges and opportunities that are likely to influence future market trends and investment strategies. The cross-regional analysis not only emphasizes the need for localized market approaches but also underscores the importance of a cohesive global strategy to tap into growth avenues and future-proof advances in antibody technology.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

A focused examination of leading key companies reveals a competitive landscape marked by continuous innovation, strategic collaborations, and robust research pipelines. Names such as Absolute Antibody Ltd. and Agilent Technologies, Inc. have built formidable reputations through their dedication to quality and technological advancements. Companies like Atlas Antibodies and AvantGen, Inc. have consistently contributed by pushing the boundaries in product development and customer-centric solutions, while industry giants such as Becton, Dickinson and Company and Bio X Cell have leveraged their extensive portfolios to capture significant market shares. Bio-Rad Laboratories, Inc. along with Bio-Techne Corporation and Cell Signaling Technology, Inc. have similarly demonstrated a commitment to integrating advanced technologies with strategic market initiatives. The contributions of multinational corporations such as Danaher Corporation, F. Hoffmann-La Roche AG, and Fujirebio further reinforce the importance of global alliances and the sharing of best practices. Additionally, companies like GenScript Corporation, ImmunoPrecise Antibodies Ltd., and Jackson ImmunoResearch Inc. have diversified their operational approaches to benefit both research and diagnostic sectors. The steady progression of companies including Lonza Group Ltd., Merck KGaA, and PerkinElmer, Inc. is indicative of the market's transformative nature. Furthermore, players such as PROGEN Biotechnik GmbH, Proteintech Group, Inc., QIAGEN N.V., Revvity, Inc., Rockland Immunochemicals, Inc., Santa Cruz Biotechnology Inc., Synaptic Systems GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc. have all made significant strides by aligning their strategic vision with cutting-edge technological innovations. This array of key companies collectively illustrates a vibrant ecosystem that is poised to continue driving innovation, efficiency, and market growth in the antibody sector.

The report delves into recent significant developments in the Research Antibodies Market, highlighting leading vendors and their innovative profiles. These include Absolute Antibody Ltd., Agilent Technologies, Inc., Atlas Antibodies, AvantGen, Inc., Becton, Dickinson and Company, Bio X Cell, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cell Signaling Technology, Inc., Danaher Corporation, Enzo Life Sciences, Inc., F. Hoffmann-La Roche AG, Fujirebio, GenScript Corporation, ImmunoPrecise Antibodies Ltd., Jackson ImmunoResearch Inc., Lonza Group Ltd., Merck KGaA, PerkinElmer, Inc., PROGEN Biotechnik GmbH, Proteintech Group, Inc., QIAGEN N.V., Revvity, Inc., Rockland Immunochemicals, Inc., Santa Cruz Biotechnology Inc., Synaptic Systems GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are positioned to leverage the rapidly evolving antibody market by adopting proactive and agile strategic approaches. It is essential for decision-makers to invest in state-of-the-art production methodologies and next-generation screening technologies to shorten development timelines and improve product quality. Additionally, fostering cross-functional collaborations between research entities and industry experts can accelerate innovation and ensure that emerging therapeutic needs are rapidly addressed. Leaders should also prioritize investments in robust regulatory compliance frameworks to navigate the complexities inherent in global markets, ensuring that advancements in antibody research translate into safe and effective clinical applications. As market competition intensifies, tailored strategies that emphasize quality, efficiency, and patient-centered outcomes will be critical. Furthermore, companies should explore opportunities to diversify their product portfolios by tapping into varied segmentation opportunities, from advanced production methods to emerging application fields. Such comprehensive strategies will empower organizations to not only maintain a competitive edge but also to capitalize on new growth avenues within a rapidly transforming market environment.

Conclusion and Future Outlook

The antibody market stands at the confluence of technological innovation and critical healthcare needs, offering unprecedented opportunities for strategic growth and development. As the industry trends shift towards more precise therapeutic interventions and innovative diagnostic methods, market participants must stay ahead by adopting agile and forward-thinking strategies. The lessons drawn from segmented analyses-inclusive of product types, technological innovations, targeted areas, and regional nuances-collectively underscore a vibrant market landscape. Companies are compelled to continuously innovate and adapt to the evolving dynamics driven by regulatory changes and technological advancements. Moreover, by aligning strategic investments with emerging market trends, stakeholders can both mitigate risks and harness the potential of untapped markets. This transformative journey, marked by collaborative innovation and strategic foresight, is set to redefine the boundaries of antibody research and commercialization in the years ahead. Looking forward, the ongoing convergence of innovation, market demand, and technological adaptation promises to foster a sustainable competitive advantage for early adopters and visionary industry leaders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic and infectious diseases globally
      • 5.1.1.2. Growing focus on personalized medicine and targeted therapy globally
      • 5.1.1.3. Rising investments in life sciences research utilizing antibodies
    • 5.1.2. Restraints
      • 5.1.2.1. High R&D costs for creating novel antibodies
    • 5.1.3. Opportunities
      • 5.1.3.1. Integrating biotechnological advances to streamline and optimize antibody production processes
      • 5.1.3.2. Enhanced focus on multi-epitope targeting antibodies to improve therapeutic efficacy across diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Addressing regulatory challenges in the approval and distribution of research antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Increasing preference for monoclonal antibodies due to their specificity and evolving biosimilar alternatives
    • 5.2.2. End User: Expanding utilization of research antibodies by pharmaceutical and biotechnology companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Research Antibodies Market, by Product Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
    • 6.2.1. Biosimilar Antibodies
    • 6.2.2. Chimeric and Humanized Antibodies
    • 6.2.3. Murine Monoclonal Antibodies
  • 6.3. Polyclonal Antibodies
    • 6.3.1. Goat Polyclonal Antibodies
    • 6.3.2. Rabbit Polyclonal Antibodies
  • 6.4. Recombinant Antibodies
    • 6.4.1. In Vitro Recombinant Antibodies
    • 6.4.2. In Vivo Recombinant Antibodies

7. Research Antibodies Market, by Technology

  • 7.1. Introduction
  • 7.2. Biotin-Avidin Method
  • 7.3. Cell-Surface Exposure
  • 7.4. Recombinant Antibody Technology
  • 7.5. Ultracentrifugation

8. Research Antibodies Market, by Target Area

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Infectious Diseases
  • 8.4. Neurology
    • 8.4.1. Central Nervous System
    • 8.4.2. Peripheral Nervous System
  • 8.5. Oncology

9. Research Antibodies Market, by Source Type

  • 9.1. Introduction
  • 9.2. Chicken
  • 9.3. Goat
  • 9.4. Mice
  • 9.5. Rabbit

10. Research Antibodies Market, by Technology Type

  • 10.1. Introduction
  • 10.2. Hybridoma Technology
  • 10.3. In Silico Antibody Screening
  • 10.4. Phage Display
  • 10.5. Single Domain Antibody Technology

11. Research Antibodies Market, by Conjugate Type

  • 11.1. Introduction
  • 11.2. Biotin
  • 11.3. Enzymes
  • 11.4. Fluorescent Dyes
  • 11.5. Gold

12. Research Antibodies Market, by Production Method

  • 12.1. Introduction
  • 12.2. In Vitro Production
  • 12.3. In Vivo Production

13. Research Antibodies Market, by Application

  • 13.1. Introduction
  • 13.2. Flow Cytometry
  • 13.3. Immunofluorescence
  • 13.4. Immunohistochemistry
    • 13.4.1. Formalin-Fixed Paraffin-Embedded Tissues
    • 13.4.2. Frozen Tissues
  • 13.5. Western Blotting

14. Research Antibodies Market, by End User

  • 14.1. Introduction
  • 14.2. Academic And Research Institutes
    • 14.2.1. Basic Research
    • 14.2.2. Translational Research
  • 14.3. Contract Research Organizations
    • 14.3.1. Analytical Services
    • 14.3.2. Preclinical Research
  • 14.4. Pharmaceutical And Biotechnology Companies
    • 14.4.1. Clinical Trials
    • 14.4.2. Research And Development

15. Americas Research Antibodies Market

  • 15.1. Introduction
  • 15.2. Argentina
  • 15.3. Brazil
  • 15.4. Canada
  • 15.5. Mexico
  • 15.6. United States

16. Asia-Pacific Research Antibodies Market

  • 16.1. Introduction
  • 16.2. Australia
  • 16.3. China
  • 16.4. India
  • 16.5. Indonesia
  • 16.6. Japan
  • 16.7. Malaysia
  • 16.8. Philippines
  • 16.9. Singapore
  • 16.10. South Korea
  • 16.11. Taiwan
  • 16.12. Thailand
  • 16.13. Vietnam

17. Europe, Middle East & Africa Research Antibodies Market

  • 17.1. Introduction
  • 17.2. Denmark
  • 17.3. Egypt
  • 17.4. Finland
  • 17.5. France
  • 17.6. Germany
  • 17.7. Israel
  • 17.8. Italy
  • 17.9. Netherlands
  • 17.10. Nigeria
  • 17.11. Norway
  • 17.12. Poland
  • 17.13. Qatar
  • 17.14. Russia
  • 17.15. Saudi Arabia
  • 17.16. South Africa
  • 17.17. Spain
  • 17.18. Sweden
  • 17.19. Switzerland
  • 17.20. Turkey
  • 17.21. United Arab Emirates
  • 17.22. United Kingdom

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Scenario Analysis
    • 18.3.1. AbbVie partners with EvolveImmune to advance novel multispecific antibodies for solid and hematologic cancers
    • 18.3.2. Atlas Antibodies unveils MolBoolean advancing neuroscience research
    • 18.3.3. Johnson & Johnson's acquisition of Ambrx transforms cancer treatment through advanced antibody drug conjugate technology
    • 18.3.4. Danaher Completes Acquisition of Abcam
    • 18.3.5. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
    • 18.3.6. AbCellera and Canada to invest $500M+ to boost antibody manufacturing and research
  • 18.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Absolute Antibody Ltd.
  • 2. Agilent Technologies, Inc.
  • 3. Atlas Antibodies
  • 4. AvantGen, Inc.
  • 5. Becton, Dickinson and Company
  • 6. Bio X Cell
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Bio-Techne Corporation
  • 9. Cell Signaling Technology, Inc.
  • 10. Danaher Corporation
  • 11. Enzo Life Sciences, Inc.
  • 12. F. Hoffmann-La Roche AG
  • 13. Fujirebio
  • 14. GenScript Corporation
  • 15. ImmunoPrecise Antibodies Ltd.
  • 16. Jackson ImmunoResearch Inc.
  • 17. Lonza Group Ltd.
  • 18. Merck KGaA
  • 19. PerkinElmer, Inc.
  • 20. PROGEN Biotechnik GmbH
  • 21. Proteintech Group, Inc.
  • 22. QIAGEN N.V.
  • 23. Revvity, Inc.
  • 24. Rockland Immunochemicals, Inc.
  • 25. Santa Cruz Biotechnology Inc.
  • 26. Synaptic Systems GmbH
  • 27. Sysmex Corporation
  • 28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. RESEARCH ANTIBODIES MARKET MULTI-CURRENCY
  • FIGURE 2. RESEARCH ANTIBODIES MARKET MULTI-LANGUAGE
  • FIGURE 3. RESEARCH ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 4. RESEARCH ANTIBODIES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 23. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 25. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 29. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 31. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 32. EUROPE, MIDDLE EAST & AFRICA RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 33. EUROPE, MIDDLE EAST & AFRICA RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 34. RESEARCH ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 35. RESEARCH ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RESEARCH ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RESEARCH ANTIBODIES MARKET DYNAMICS
  • TABLE 7. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY BIOSIMILAR ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CHIMERIC AND HUMANIZED ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY MURINE MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY GOAT POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY RABBIT POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY IN VITRO RECOMBINANT ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY IN VIVO RECOMBINANT ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY BIOTIN-AVIDIN METHOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CELL-SURFACE EXPOSURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PERIPHERAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CHICKEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY GOAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY MICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY RABBIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY IN SILICO ANTIBODY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PHAGE DISPLAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY SINGLE DOMAIN ANTIBODY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY BIOTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY FLUORESCENT DYES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY GOLD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY IN VITRO PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY IN VIVO PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY FROZEN TISSUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 84. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 86. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 88. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 90. AMERICAS RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 93. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 94. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 95. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 97. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 104. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 106. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. ARGENTINA RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 108. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 110. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 111. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 112. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 114. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 119. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 121. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 123. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. BRAZIL RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 125. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 127. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 128. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 129. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 131. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 136. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 138. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 140. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. CANADA RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 142. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 144. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 145. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 146. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 148. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 153. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 155. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 157. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. MEXICO RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 159. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 161. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 162. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 163. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 165. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 170. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 172. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 174. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 176. UNITED STATES RESEARCH ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC RESEARCH ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 195. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 197. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 198. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 199. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 202. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 206. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 208. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 210. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 212. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 214. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 215. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 216. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 218. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 223. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 225. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 227. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. CHINA RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 229. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 231. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 232. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 233. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 235. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 240. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 242. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 244. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 245. INDIA RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 246. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 248. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 249. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 250. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 252. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 257. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 259. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 261. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 262. INDONESIA RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 263. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 265. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 266. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 267. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 268. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 269. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 270. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 274. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 276. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 278. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 279. JAPAN RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 280. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 282. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 283. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 284. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 285. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 286. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 291. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 293. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 294. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 295. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 296. MALAYSIA RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 297. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 299. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 300. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 301. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 302. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 303. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 308. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 309. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)
  • TABLE 310. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 311. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 312. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 313. PHILIPPINES RESEARCH ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 314. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 316. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 317. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY RECOMBINANT ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 318. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 319. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY TARGET AREA, 2018-2030 (USD MILLION)
  • TABLE 320. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 321. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY CONJUGATE TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY PRODUCTION METHOD, 2018-2030 (USD MILLION)
  • TABLE 325. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 326. SINGAPORE RESEARCH ANTIBODIES MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2030 (USD MILLION)

T